Life Science Items of Interest: SmartBrief

Showing posts with label SmartBrief. Show all posts

Friday, April 12, 2013

Before you visit the exhibit hall at an annual conference or scientific session, how much planning do you do?

Before you visit the exhibit hall at an annual conference or scientific session, how much planning do you do?

I arrive with a list of whom I will meet and which exhibits I will visit.

I have an idea of whom I will meet and what exhibits I will visit, but I want to see what else catches my attention.

I have no plan beyond finding out which exhibits are interesting.

Tuesday, April 9, 2013

Japanese drugmakers, government team up to fight disease

Sign up today to have the latest news in drug development worldwide delivered to your inbox ~ DIA's Global Smartbrief

Japan's government has joined the Bill and Melinda Gates Foundation as well as drugmakers Astellas, Eisai, Daiichi-Sankyo, Shionogi and Takeda to form the Global Health Innovative Technology fund to develop diagnostic tests, drugs and vaccines to fight disease in developing countries. The group will collaborate on research with significant impact, says Dr. Kiyoshi Kurokawa, the fund's chairman. The Japan Daily Press(4/8)

For complete article, http://japandailypress.com/japanese-pharma-companies-to-help-medicine-research-in-developing-countries-0826592

Thursday, March 14, 2013

Indian Supreme Court, Clinical trials, and Pharma growth

Reading this on a mobile device? Try our optimized mobile version here:http://r.smartbrief.com/resp/enjcCmnpecCigKaRCidyfTDXBJfyrv

March 14, 2013

Forward

Archive

Advertise

Indian court: No need for vegetarian/non-vegetarian labels
The Indian Supreme Count rejected a lower-court ruling requiring "V" and "NV" labels identifying drugs and cosmetics as either vegetarian or non-vegetarian in origin. In opposing the regulation, the government noted the variability in individual food habits, including broad differences even among vegetarians concerning which foods are acceptable and which are not. The Economic Times (India)(3/12)

Deaths in Indian clinical trials result in few payments
While 2,868 deaths were reported during clinical trials from 2005 to 2012, the Indian government found only 89 to be directly attributable to the trials. To date, compensation has been paid in only 45 cases. The government has established four committees to monitor the fast-growing growing clinical-trial industry in India, mandating strict requirements for reporting adverse events, including deaths, according to the Ministry of Health and Family Welfare. Business Standard (India)(3/13)

To grow, Indian pharma must embrace innovation, technology
Indian drug companies must focus on new technologies, including development of "super-generics," in order to grow and flourish, said Andrew Barrett, director of medical technology in India at Cambridge Consultants. "[T]he required investments can be recouped because medical products have long lifecycles," he added. Other experts at a Mumbai conference noted that the biggest growth opportunities will come from innovations to differentiate products, because the number of expiring drug patents has peaked, and other countries are offering greater competition for low-cost generics. PharmaTimes (U.K.)(3/13)

Subscriber Tools

Advertise

Account Director, Life Sciences: Meryl Harold (202) 407-7828

Thursday, February 28, 2013

Japan "best market in the world" for foreign drugmakers

Japan "best market in the world" for foreign drugmakers
Japan is enjoying the benefits of changing the way it reviews, administers and pays for drugs in an effort to spur innovation and address rising costs associated with aging. "For foreign [drug] companies, it's the best market in the world right now," PhRMA representative Ira Wolf said. The country has accelerated the review of new treatments, placed the pricing system under review and set a 30% market share goal for generics. The Economist (tiered subscription model)(2/22)

Subscriber Tools

Advertise

Account Director, Life Sciences: Meryl Harold (202) 407-7828

Groups to Ala. Supreme Court: Reconsider generic-drugs decision

Groups to Ala. Supreme Court: Reconsider generic-drugs decision
Business groups led by the U.S. Chamber of Commerce and the Pharmaceutical Research and Manufacturers of America are pressing the Alabama Supreme Court to reconsider its ruling that makes brand-name drugmakers liable for injuries caused by generic versions of their treatments. "By essentially absolving [generic-drug-makers] of any responsibility, you're saying they don't have to perform that job very carefully," PhRMA General Counsel Mit Spears said. In a separate court brief, the Chamber of Commerce said the decision "threatens to unleash the plaintiffs' bar on all manufacturers doing business in Alabama" and "eviscerates basic tort limitations." The Wall Street Journal(2/24)

Subscriber Tools

Advertise

Account Director, Life Sciences: Meryl Harold (202) 407-7828

Report: Fifth of global generic drugs produced in India

Report: Fifth of global generic drugs produced in India
India manufactures 20% of the world's generic injectables, capsules and tablets, according to data released by Union Health Minister Ghulam Nabi Azad. "The Industry is ranked third globally in volume and 14th in value, supplying around 10% of total global production," Azad said. "This also amounts to around 20% of total volume of global generics." PharmaBiz.com (India)(2/23)

Subscriber Tools

Advertise

Account Director, Life Sciences: Meryl Harold (202) 407-7828

Friday, February 22, 2013

Using MRCTs in new drug development

DIA Global SmartBrief | Feb 07, 2013

Multiregional clinical trials (MRCTs) in East Asia, including Japan, China, Korea and Taiwan, are now considered one of the promising key strategic options in new drug development. The 7th Annual Conference for Asian New Drug Development, to be held in Tokyo, Japan, from April 15 to 16, will provide a forum for exchange of opinions among regulatory agencies in East Asia about how increasing MRCT data should be used in new drug applications in the region. Read more.

Thursday, February 14, 2013

Collaboration — The hot topic at LARC 2013

Collaboration — The hot topic at LARC 2013

Global regulators, industry professionals and academia will gather at the Latin American Regulatory Conference (LARC) 2013, to be held in Colombia, May 15 to 16. The event, titled "Pharma-co-vergence," aims to assist drug regulatory authorities to work in a collaborative way to best utilize resources for promoting improved public health globally. Attendees will discuss the current regulatory landscape, future research and drug development in Latin America. Find out more.


	Recent DIA Global SmartBrief Issues: Tuesday, February 12, 2013 Thursday, February 07, 2013 Tuesday, February 05, 2013 Thursday, January 31, 2013 Tuesday, January 29, 2013			Lead Editor: Lisa Gough Mailing Address: SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004

Life Science Items of Interest

Friday, April 12, 2013

Before you visit the exhibit hall at an annual conference or scientific session, how much planning do you do?

Tuesday, April 9, 2013

Japanese drugmakers, government team up to fight disease

Thursday, March 14, 2013

Indian Supreme Court, Clinical trials, and Pharma growth

Thursday, February 28, 2013

Japan "best market in the world" for foreign drugmakers

Groups to Ala. Supreme Court: Reconsider generic-drugs decision

Report: Fifth of global generic drugs produced in India

Friday, February 22, 2013

Using MRCTs in new drug development

Thursday, February 14, 2013

Collaboration — The hot topic at LARC 2013

Follow us:

Total Pageviews